Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356708 | 1.00 | MAPT (0.43) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL18605502 | 0.87 | ALDH1A1 (0.41) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL23057745 | 0.81 | LIPE (0.33) | CA1CA2CA9 | |
| SCHEMBL29973522 | 0.81 | LIPE (0.33) | CA1CA2CA9 | |
| SCHEMBL29424578 | 0.81 | CA2 (0.47) | MAPTALDH1A1EGFRCYP3A4CA1 | |
| SCHEMBL5899720 | 0.81 | CA2 (0.47) | MAPTALDH1A1EGFRCYP3A4CA1 | |
| SCHEMBL15334799 | 0.81 | ACHE (0.47) | MAPTMAPK1ALDH1A1KDM4EEGFR | |
| SCHEMBL2658964 | 0.80 | LPL (0.45) | KDM4EEGFRCSF1RCA1CA2 | |
| SCHEMBL16282205 | 0.80 | EGFR (0.47) | MAPTTSHRMAPK1ALDH1A1KDM4E | |
| SCHEMBL257903 | 0.80 | MAOB (0.47) | MAPTGAAEGFRCYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661966-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | Type6 Therapeutics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12473296-B2 | Perk inhibiting compounds | HIBERCELL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12331054-B2 | Perk inhibiting imidazolopyrazine compounds | HIBERCELL, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2024167848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | TYPE6 THERAPEUTICS, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220348583-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220332722-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. | 2022-10-20 | — | — | US | disclosed |
| WO-2022216717-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332722-A1 | PERK INHIBITING COMPOUNDS | ATF4, EEF2K, ERN1 | MAPT 1801/4885GAA 1045/4885TSHR 4112/4885 |
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | EEF2K, ATF4, MAPKAPK2 | MAPT 2006/4885GAA 1521/4885TSHR 3965/4885 |
| US-20220348583-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | MAPKAPK2, MAPK4, MAP3K5 | MAPT 1998/4885GAA 2109/4885TSHR 3831/4885 |
| US-12331054-B2 | Perk inhibiting imidazolopyrazine compounds | MAPKAPK2, MAPK4, MAP3K5 | MAPT 1998/4885GAA 2109/4885TSHR 3831/4885 |
| US-12473296-B2 | Perk inhibiting compounds | MAPK1, ERN1, MAP3K20 | MAPT 1640/4885GAA 110/4885TSHR 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.